Thomas Geisbert, PhD, MS

Projects

Projects per year 2010 2012 2014 2017 2019 2020 2026

• 82 Active
• 185 Completed

Projects per year

Search results

• Active

  Marburg Virus Prophylactic Medical Countermeasure

  Geisbert, T.

  4/6/22 → 2/28/23

  Project: Other project

• Marburg Virus Prophylactic Medical Countermeasure

  Geisbert, T.

  4/6/22 → 2/28/23

  Project: Other project

• Efficacy of Marburg virus monoclonal antibody (IBT-T03) in guinea pig model of MARV-Angola infection

  Geisbert, T.

  11/11/21 → 6/1/22

  Project: Other project

• Efficacy of Marburg virus monoclonal antibody (IBT-T03) in guinea pig model of MARV-Angola infection

  Geisbert, T.

  11/11/21 → 6/1/22

  Project: Other project

• Determination of the EC50 and EC90 of favipiravir against SARS-CoV-2

  Geisbert, T.

  10/1/21 → 8/31/22

  Project: Other project

• Determination of the EC50 and EC90 of favipiravir against SARS-CoV-2

  Geisbert, T.

  10/1/21 → 8/31/22

  Project: Other project

• Development of an aerosol induced nonhuman primate model of Lassa fever

  Geisbert, T.

  7/30/21 → 8/31/26

  Project: Other project

• Development of an aerosol induced nonhuman primate model of Lassa fever

  Geisbert, T.

  7/30/21 → 8/31/26

  Project: Other project

• Development of an aerosol induced nonhuman primate model of Lassa fever

  Geisbert, T.

  7/30/21 → 8/31/26

  Project: Other project

• In Vitro Lassa Virus Resistance Studies with ARN-75039

  Geisbert, T.

  6/1/21 → 6/30/22

  Project: Other project

• Antiviral Efficacy Assessment of Arbutus Compounds in a SARS CoV-2 Hamster Infection Model

  Geisbert, T.

  6/1/21 → 5/31/23

  Project: Other project

• In Vitro Lassa Virus Resistance Studies with ARN-75039

  Geisbert, T.

  6/1/21 → 6/30/22

  Project: Other project

• Antiviral Efficacy Assessment of Arbutus Compounds in a SARS CoV-2 Hamster Infection Model

  Geisbert, T.

  6/1/21 → 5/31/23

  Project: Other project

• Preclinical development of a vaccine for Nipah virus

  Geisbert, T.

  National Inst of Allergy & Infectious Di

  3/11/21 → 2/28/26

  Project: Other project

• Preclinical development of a vaccine for Nipah virus

  Geisbert, T.

  National Inst of Allergy & Infectious Di

  3/11/21 → 2/28/26

  Project: Other project

• Development of a rVSV-Vectored Vaccine for Lassa Virus: Nonhuman Primate Efficacy and Immunogenicity Studies

  Geisbert, T.

  1/1/21 → 12/1/24

  Project: Other project

• Development of a rVSV-Vectored Vaccine for Lassa Virus: Nonhuman Primate Efficacy and Immunogenicity Studies

  Geisbert, T.

  Emergent Product Development Gaithersbur

  1/1/21 → 12/1/24

  Project: Other project

• Development of a rVSV-Vectored Vaccine for Lassa Virus: Nonhuman Primate Efficacy and Immunogenicity Studies

  Geisbert, T.

  Emergent Product Development Gaithersbur

  1/1/21 → 12/1/24

  Project: Other project

• Preclinical Development of a Crimean-Congo Hemorrhagic Fever Virus Vaccine

  Geisbert, T.

  National Inst of Allergy & Infectious Di

  7/15/20 → 6/30/25

  Project: Other project

• Preclinical Development of a Crimean-Congo Hemorrhagic Fever Virus Vaccine

  Geisbert, T.

  7/15/20 → 6/30/25

  Project: Other project

• Preclinical Development of a Crimean-Congo Hemorrhagic Fever Virus Vaccine

  Geisbert, T.

  National Inst of Allergy & Infectious Di

  7/15/20 → 6/30/25

  Project: Other project

• Preclinical Development of a Crimean-Congo Hemorrhagic Fever Virus Vaccine

  Geisbert, T.

  7/15/20 → 6/30/25

  Project: Other project

• Authentic Live Virus Assay (up to 50 samples tested); Lilly #1

  Geisbert, T.

  4/16/20 → 4/1/23

  Project: Other project

• Authentic Live Virus Assay (up to 50 samples tested); Lilly #1

  Geisbert, T.

  4/16/20 → 4/1/23

  Project: Other project

• Authentic Live Virus Assay (up to 50 samples tested); Lilly #1

  Geisbert, T.

  Eli Lilly & Company

  4/16/20 → 4/1/23

  Project: Other project

• Authentic Live Virus Assay (up to 50 samples tested); Lilly #1

  Geisbert, T.

  4/16/20 → 4/1/23

  Project: Other project

• Authentic Live Virus Assay (up to 50 samples tested); Lilly #1

  Geisbert, T.

  4/16/20 → 4/1/23

  Project: Other project

• Authentic Live Virus Assay (up to 50 samples tested); Lilly #1

  Geisbert, T.

  4/16/20 → 4/1/23

  Project: Other project

• Authentic Live Virus Assay (up to 50 samples tested); Lilly #1

  Geisbert, T.

  4/16/20 → 4/1/23

  Project: Other project

• Development of a Recombinant VSV-Based Vaccine for Nipah Virus

  Geisbert, T.

  9/1/19 → 8/31/22

  Project: Other project

• Development of a Recombinant VSV-Based Vaccine for Lassa Fever

  Geisbert, T.

  9/1/19 → 8/31/22

  Project: Other project

• Development of a Recombinant VSV-Based Vaccine for Lassa Fever

  Geisbert, T.

  9/1/19 → 8/31/22

  Project: Other project

• Development of a Recombinant VSV-Based Vaccine for Nipah Virus

  Geisbert, T.

  9/1/19 → 8/31/22

  Project: Other project

• A Vaccine for Prevention of Lassa Fever Based on a Live Vesicular Stomatitis Virus-Lassa Virus Chimera

  Geisbert, T.

  3/27/19 → 9/30/22

  Project: Other project

• A Vaccine for Prevention of Lassa Fever Based on a Live Vesicular Stomatitis Virus-Lassa Virus Chimera

  Geisbert, T.

  3/27/19 → 9/30/22

  Project: Other project

• A Vaccine for Prevention of Lassa Fever Based on a Live Vesicular Stomatitis Virus-Lassa Virus Chimera

  Geisbert, T.

  3/27/19 → 9/30/22

  Project: Other project

• A Vaccine for Prevention of Lassa Fever Based on a Live Vesicular Stomatitis Virus-Lassa Virus Chimera

  Geisbert, T.

  3/27/19 → 9/30/22

  Project: Other project

• A Vaccine for Prevention of Lassa Fever Based on a Live Vesicular Stomatitis Virus-Lassa Virus Chimera

  Geisbert, T.

  3/27/19 → 9/30/22

  Project: Other project

• Advancement of Vaccines and Therapies for Henipaviruses

  Geisbert, T.

  3/20/19 → 2/28/23

  Project: Other project

• ADVANCEMENT OF VACCINES AND TREATMENTS FOR EBOLA AND MARBURG VIRUS INFECTIONS

  Geisbert, T.

  3/8/19 → 2/29/24

  Project: Other project

• ADVANCEMENT OF VACCINES AND TREATMENTS FOR EBOLA AND MARBURG VIRUS INFECTIONS

  Geisbert, T.

  3/8/19 → 2/29/24

  Project: Other project

• ADVANCEMENT OF VACCINES AND TREATMENTS FOR EBOLA AND MARBURG VIRUS INFECTIONS

  Geisbert, T.

  National Inst of Allergy & Infectious Di

  3/8/19 → 2/29/24

  Project: Other project

• ADVANCEMENT OF VACCINES AND TREATMENTS FOR EBOLA AND MARBURG VIRUS INFECTIONS

  Geisbert, T.

  National Inst of Allergy & Infectious Di

  3/8/19 → 2/29/24

  Project: Other project

• ADVANCEMENT OF VACCINES AND TREATMENTS FOR EBOLA AND MARBURG VIRUS INFECTIONS

  Geisbert, T.

  National Inst of Allergy & Infectious Di

  3/8/19 → 2/29/24

  Project: Other project

• ADVANCEMENT OF VACCINES AND TREATMENTS FOR EBOLA AND MARBURG VIRUS INFECTIONS

  Geisbert, T.

  3/8/19 → 2/29/24

  Project: Other project

• ADVANCEMENT OF VACCINES AND TREATMENTS FOR EBOLA AND MARBURG VIRUS INFECTIONS

  Geisbert, T.

  3/8/19 → 2/29/24

  Project: Other project

• ADVANCEMENT OF VACCINES AND TREATMENTS FOR EBOLA AND MARBURG VIRUS INFECTIONS

  Geisbert, T.

  National Inst of Allergy & Infectious Di

  3/8/19 → 2/29/24

  Project: Other project

• ADVANCEMENT OF VACCINES AND TREATMENTS FOR EBOLA AND MARBURG VIRUS INFECTIONS

  Geisbert, T.

  National Inst of Allergy & Infectious Di

  3/8/19 → 2/29/24

  Project: Other project

• ADVANCEMENT OF VACCINES AND TREATMENTS FOR EBOLA AND MARBURG VIRUS INFECTIONS

  Geisbert, T.

  3/8/19 → 2/29/24

  Project: Other project

• ADVANCEMENT OF VACCINES AND TREATMENTS FOR EBOLA AND MARBURG VIRUS INFECTIONS

  Geisbert, T.

  National Inst of Allergy & Infectious Di

  3/8/19 → 2/29/24

  Project: Other project